Macquarie Group Ceases to Be Substantial Holder in Australian Clinical Labs

Macquarie Group Limited ( (AU:MQG) ) has shared an announcement.

Macquarie Group Limited has filed a notice stating it has ceased to be a substantial holder in Australian Clinical Labs Limited, indicating that its voting power in the pathology company has fallen below the substantial holding threshold. The change, formalised in an Australian Corporations Act Form 605 and signed by Company Secretary Simone Kovacic on 8 April 2026, reflects adjustments in relevant interests and associations among Macquarie-controlled entities, signalling a retreat from a significant equity position in Australian Clinical Labs.

The notice lists Macquarie Group and a wide range of its controlled bodies corporate, underscoring the breadth of the group’s investment structures that were previously associated with the holding. For investors and the market, Macquarie’s exit as a substantial shareholder may alter the shareholder register dynamics and could affect perceptions of institutional support and liquidity in Australian Clinical Labs’ stock, even though detailed transaction terms were not disclosed in the filing.

The most recent analyst rating on (AU:MQG) stock is a Buy with a A$235.00 price target. To see the full list of analyst forecasts on Macquarie Group Limited stock, see the AU:MQG Stock Forecast page.

More about Macquarie Group Limited

Macquarie Group Limited is a global financial services group headquartered in Sydney, providing banking, investment management and advisory services. Through subsidiaries such as Macquarie Bank Limited and Macquarie Investment Management entities, it operates across capital markets, asset management and structured finance for institutional and corporate clients worldwide.

Average Trading Volume: 804,847

Technical Sentiment Signal: Buy

Current Market Cap: A$75.15B

Find detailed analytics on MQG stock on TipRanks’ Stock Analysis page.